Neurotech International Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. Its product includes Mente Autism, a portable electroencephalographic medical device that uses neuro feedback to relax the minds of children with autism spectrum disorder. The company focuses on developing neuro-stimulation and neuro-diagnostic solutions that enable medical practitioners to monitor and play an active role in home-based therapies. It also engages in executing of medical research projects; and developing of technological devices and other solutions for the screening and treatment of neurological disorders. The company was incorporated in 2016 and is based in Nedlands, Australia.
|Primary activities||Development of wearable neurotechnology devices to assist with neurological conditions such as autism.|
|Industry / Sector||Medical Devices / Healthcare|
|Mailing address||145 Stirling Highway Suite 5 CPC Nedlands WA 6009 Australia|
|Phone / Fax||61 8 9389 3130 / 61 8 9389 3199|
|Share registry||AUTOMIC REGISTRY SERVICES|
Neurotech International does not pay dividends.
As of May 2021, following are the company executives and directors listed on Neurotech International.
|Mr. Peter James Lawrence Griffiths B.Sc.||Chief Exec. Officer||56||282.17k|
|Dr. Emanuela Russo||Chief Scientific Officer & Member of Scientific Advisory Board|
|Ms. Erlyn Saromines Dale A.C.I.S., B.Com., BCom., GradDipACG, AGIA, ACIS||Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Neurotech International is 37.78M and its enterprise value is 31.64M. The enterprise value to revenue ratio of NTI is 443.88.
The NTI's stocks Beta value is 2.69 making it 169% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Neurotech International (NTI)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Neurotech International (ASX:NTI) Frequently Asked Questions
1. What is Neurotech International's Stock Symbol?
Neurotech International trades on ASX under the ticker symbol "NTI".
2. What is Neurotech International's stock price today?
One share of NTI stock can currently be purchased for approximately $0.055.
3. How can I contact Neurotech International?
Neurotech International's mailing address is 145 Stirling Highway Suite 5 CPC Nedlands WA 6009 Australia. The company can be reached via phone at 61 8 9389 3130.
4. What is Neurotech International's official website?
The official website of Neurotech International is http://www.neurotechinternational.com.
5. Which share registry manages Neurotech International's stock?
Neurotech International's stock is managed by AUTOMIC REGISTRY SERVICES.